Publication: A Comparative Effectiveness Analysis Applying a 3-Way Propensity Score Matching to Real-World Data from the MSBase Registry in Preparation for a Cost-Effectiveness Model: Patients Switching Within First-Line Agents or to Either Natalizumab or Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
| dc.contributor.author | Spelman, Timothy | |
| dc.contributor.author | Havrdova, Eva | |
| dc.contributor.author | Horakova, Dana | |
| dc.contributor.author | Trojano, Maria | |
| dc.contributor.author | Lugaresi, Alessandra | |
| dc.contributor.author | Izquierdo, Guillermo | |
| dc.contributor.author | Butzkueven, Helmut | |
| dc.contributor.authorID | Lugaresi, Alessandra/0000-0003-2902-5589 | |
| dc.date.accessioned | 2020-06-21T13:11:21Z | |
| dc.date.available | 2020-06-21T13:11:21Z | |
| dc.date.issued | 2018 | |
| dc.department | OMÜ | en_US |
| dc.department-temp | [Spelman, Timothy -- Jokubaitis, Vilija -- Butzkueven, Helmut] Royal Melbourne Hosp, Melbourne, Vic, Australia -- [Spelman, Timothy -- Kalincik, Tomas] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia -- [Kalincik, Tomas] Univ Melbourne, Dept Med, CORe Unit, Melbourne, Vic, Australia -- [Havrdova, Eva | en_US |
| dc.description | 70th Annual Meeting of the American-Academy-of-Neurology (AAN) -- APR 21-27, 2018 -- Los Angeles, CA | en_US |
| dc.description.abstract | … | en_US |
| dc.description.sponsorship | Amer Acad Neurol | en_US |
| dc.description.sponsorship | Biogen International (Zug, Switzerland) | en_US |
| dc.description.sponsorship | Study Supported by: Biogen International (Zug, Switzerland). | en_US |
| dc.identifier.issn | 0028-3878 | |
| dc.identifier.issn | 1526-632X | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/11676 | |
| dc.identifier.volume | 90 | en_US |
| dc.identifier.wos | WOS:000453090800355 | |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott Williams & Wilkins | en_US |
| dc.relation.journal | Neurology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | A Comparative Effectiveness Analysis Applying a 3-Way Propensity Score Matching to Real-World Data from the MSBase Registry in Preparation for a Cost-Effectiveness Model: Patients Switching Within First-Line Agents or to Either Natalizumab or Fingolimod in Active Relapsing-Remitting Multiple Sclerosis | en_US |
| dc.type | Conference Object | en_US |
| dspace.entity.type | Publication |